Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
10:25am, Thursday, 13'th Nov 2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focu
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
09:22am, Thursday, 13'th Nov 2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focu
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
02:40am, Thursday, 13'th Nov 2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focu
Inventiva announces launch of public offering
04:25pm, Wednesday, 12'th Nov 2025
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focu
Inventiva Announces the Implementation of a New ATM Program
04:00pm, Tuesday, 14'th Oct 2025
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical comp
Inventiva S.A. (IVA) Analyst/Investor Day Transcript
07:16pm, Wednesday, 08'th Oct 2025
Inventiva S.A. (NASDAQ:IVA ) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Developm
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
04:00pm, Tuesday, 07'th Oct 2025
Daix (France), New York City (New York, United States), October 7, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compan
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
02:30am, Wednesday, 01'st Oct 2025
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:06am, Monday, 29'th Sep 2025
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
02:30am, Monday, 29'th Sep 2025
Daix (France), New York City (New York, United States), September 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical com
Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings
02:26am, Monday, 29'th Sep 2025
Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept.
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now
10:56am, Friday, 26'th Sep 2025
Inventiva (IVA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall
Inventiva to Host Analyst and Investor Event on October 8, 2025
04:00pm, Wednesday, 24'th Sep 2025
Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical co
Inventiva to Participate in Upcoming September Investor Conferences
04:00pm, Thursday, 04'th Sep 2025
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical com
How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%
10:56am, Friday, 29'th Aug 2025
The mean of analysts' price targets for Inventiva (IVA) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
